| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6017457 | Experimental Neurology | 2015 | 4 Pages |
Abstract
Growing evidence indicates that chemokines participate in the generation and maintenance of bone cancer pain (BCP). Recent work in Exp Neurol by Guan et al. (2015) demonstrated the involvement of spinal chemokine receptor CXCR3 and its downstream PI3K/Akt and Raf/MEK/ERK signaling pathways in BCP. This work provides new evidence to support that chemokines participate in central sensitization in BCP condition. Reviewed evidence suggests that few chemokines have been proved to be related to cancer pain. The underlying relationship between CXCR3 signaling and BCP condition requires further study.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Genhua Guo, Feng Gao,